-
公开(公告)号:KR101116756B1
公开(公告)日:2012-03-13
申请号:KR1020090102359
申请日:2009-10-27
Applicant: 한국과학기술연구원
IPC: C07D403/04 , C07D209/04 , A61K31/40 , A61P35/00
CPC classification number: C07D403/04 , A61K31/404 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04
Abstract: 본 발명은 단백질 키나아제 저해활성을 갖는 1,6-치환된 인돌 화합물, 이의 약학적으로 허용 가능한 염, 그리고 이 화합물을 유효성분으로 함유하는 비정상 세포 성장으로 유발되는 종양질환의 예방 및 치료용 약학적 조성물에 관한 것이다.
본 발명의 신규 인돌 화합물은 성장 인자 신호 전달에 관여하는 다양한 단백질 키나아제에 대하여 우수한 억제 효과를 나타내므로, 이들 단백질 키나아제에 의해 유발되는 종양 질환의 예방 및 치료제로서 유용하다.
인돌, 단백질, 키나아제, 억제제, 비정상 세포 성장 질환-
2.
公开(公告)号:KR1020110044053A
公开(公告)日:2011-04-28
申请号:KR1020090100867
申请日:2009-10-22
Applicant: 한국과학기술연구원
IPC: C07D495/04 , C07D495/02 , A61K31/505 , A61P35/00
CPC classification number: C07D495/04 , C07D519/00
Abstract: PURPOSE: A 2,7-substituted thieno[3,2-d]pyrimidine compound is provided to ensure excellent effect of suppressing various protein kinases and to prevent and treat abnormal cell growth diseases. CONSTITUTION: A 2,7-substituted thieno[3,2-d]pyrimidine compound is denoted by chemical formula 1. A pharmaceutical composition contains the compound of chemical formula 1 as an active ingredient. The pharmaceutical composition is used for preventing and treating abnormal cell growth diseases through ALK, Aurora A, EphA1, FAK, Flt3, Fms, Itk, KDR, Kit, Met, Ret, Src, Syk, Tie2, or TrkB protein kinase suppression mechanism. An agent for preventing and treating tumor contains the compound of chemical formula 1 as an active ingredient.
Abstract translation: 目的:提供2,7-取代的噻吩并[3,2-d]嘧啶化合物,以确保抑制各种蛋白激酶和预防和治疗异常细胞生长疾病的优异效果。 构成:2,7-取代的噻吩并[3,2-d]嘧啶化合物由化学式1表示。药物组合物含有化学式1的化合物作为活性成分。 该药物组合物用于通过ALK,Aurora A,EphA1,FAK,Flt3,Fms,Itk,KDR,Kit,Met,Ret,Src,Syk,Tie2或TrkB蛋白激酶抑制机制预防和治疗异常细胞生长疾病。 用于预防和治疗肿瘤的药物含有化学式1的化合物作为活性成分。
-
公开(公告)号:KR1020110045688A
公开(公告)日:2011-05-04
申请号:KR1020090102359
申请日:2009-10-27
Applicant: 한국과학기술연구원
IPC: C07D403/04 , C07D209/04 , A61K31/40 , A61P35/00
CPC classification number: C07D403/04 , A61K31/404 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04
Abstract: PURPOSE: A 1,6-substituted indole compound with an activity of suppressing protein kinase is provided to prevent and treat tumor caused by protein kinase. CONSTITUTION: A 1,6-substituted indole compound is denoted by chemical formula 1. A pharmaceutical composition contains the 1,6-subsituted indole compound as an active ingredient. The pharmaceutical composition is used for preventing and treating tumor disease caused by mechanism of protein kinase of Raf, KDR, Fms, Tie2, SAPK2a, Ret, Abl, Abl(T315I), ALK, Aurora A, Bmx, Src, EphA1, FGFR, Flt3, Itk, JAK2, Met, PDGFR, Plk, Ret, Syk, or Trk.
Abstract translation: 目的:提供具有抑制蛋白激酶活性的1,6-取代吲哚化合物,以预防和治疗由蛋白激酶引起的肿瘤。 构成:1,6-取代的吲哚化合物由化学式1表示。药物组合物含有1,6-取代的吲哚化合物作为活性成分。 该药物组合物用于预防和治疗由Raf,KDR,Fms,Tie2,SAPK2a,Ret,Abl,Abl(T315I),ALK,Aurora A,Bmx,Src,EphA1,FGFR等蛋白激酶的机制引起的肿瘤疾病, Flt3,Itk,JAK2,Met,PDGFR,Plk,Ret,Syk或Trk。
-
4.
公开(公告)号:KR101147550B1
公开(公告)日:2012-05-17
申请号:KR1020090100867
申请日:2009-10-22
Applicant: 한국과학기술연구원
IPC: C07D495/04 , C07D495/02 , A61K31/505 , A61P35/00
CPC classification number: C07D495/04 , C07D519/00
Abstract: Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient. Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.
-
-
-